Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ASTRAZENECA : Kepler Cheuvreux reaffirms its Buy rating

11/22/2021 | 07:44am EST

In his latest research note, analyst David Evans confirms his positive recommendation. The broker Kepler Cheuvreux is keeping its Buy rating. The target price is lowered from GBX 9800 to GBX 9500.


ę MarketScreener with dpa-AFX Analyser 2021
All news about ASTRAZENECA PLC
01/20ASTRAZENECA : Deutsche Bank reaffirms its Buy rating
MD
01/20EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
RE
01/20EMA : In january 2022, prac concluded that transverse myelitis should be added to the prod..
RE
01/19India's expert panel advises full approval for Covishield, Covaxin
RE
01/19ASTRAZENECA : JP Morgan reiterates its Buy rating
MD
01/19AstraZeneca PLC Announces Positive Results from the TOPAZ-1 Phase III Trial
CI
01/19Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tr..
AQ
01/19AstraZeneca Says Liver Cancer Combination Therapy Improved Overall Survival in Late-Sta..
MT
01/19AstraZeneca Says Imfinzi Combination Shows Unprecedented Liver-Cancer Survival Rate
DJ
01/19Astrazeneca plc Announces Imfinzi Combo Shows Unprecedented Survival in HCC
CI
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 114 M - -
Net income 2021 2 714 M - -
Net Debt 2021 24 816 M - -
P/E ratio 2021 55,0x
Yield 2021 2,34%
Capitalization 186 B 187 B -
EV / Sales 2021 5,85x
EV / Sales 2022 4,80x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 120,22 $
Average target price 138,70 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC1.89%186 985
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833